Finch Therapeutics Group, Inc. (FNCH)
| Market Cap | 697.50M |
| Revenue (ttm) | 9.96M |
| Net Income (ttm) | n/a |
| Shares Out | 47.45M |
| EPS (ttm) | -2.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,772 |
| Open | 13.51 |
| Previous Close | 13.75 |
| Day's Range | 13.30 - 14.70 |
| 52-Week Range | 11.56 - 22.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 29.67 (+101.8%) |
| Est. Earnings Date | Nov 9, 2021 |
About FNCH
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of ...
Financial Performance
In 2020, FNCH's revenue was $7.72 million, a decrease of -23.98% compared to the previous year's $10.15 million. Losses were -$39.34 million, 89.6% more than in 2019.
Financial StatementsNews
Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SOMERVILLE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...
Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...
Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program
SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...
Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes
SOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...
Finch Therapeutics to Present at Upcoming Virtual Investor Conferences
SOMERVILLE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human...
Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
SOMERVILLE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or the “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First ...
Finch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care Conference
SOMERVILLE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human...
Finch Therapeutics Appoints Susan E. Graf to Board of Directors
SOMERVILLE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...
The IPO Market Had A Busy Week
Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...
Finch Therapeutics Announces Pricing of Upsized Initial Public Offering
SOMERVILLE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...
Microbiome therapy biotech Finch Therapeutics Group files for a $100 million IPO
Finch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Finch Therapeutics Group IPO Registration Document (S-1)
Finch Therapeutics Group, Inc. has filed to go public with an IPO on the NASDAQ.